Dallas, TX (Feb. 18, 2004) -- John Nemunaitis, M.D., oncologist and researcher at the Mary Crowley Medical Research Center (MCMRC) at Baylor University Medical Center at Dallas, has developed a vaccine that suppresses lung cancer in some patients. Results of the clinical trial are published in today’s Journal of the National Cancer Institute in a paper titled “Phase I/II Study of GVAX® in Non-Small Cell Lung Cancer (NSCLC).”
NSCLC is the leading cause of cancer death for men and women in the United States. More than 150,000 people die from the disease each year.
In Dr. Nemunaitis’s research trial 43 patients with early and advanced stage NSCLC were injected with the vaccine, called GVAX®. Vaccines were administered every two weeks for a total of three to six vaccinations.
“While it’s premature to call this a cure, we found that in a small number of people who were sensitive to this approach, the cancer hasn’t come back. And, for a number of patients, it has been more than three years since they received the vaccine,” said John Nemunaitis, M.D., principal investigator of the study at Baylor University Medical Center at Dallas.
Researchers developed the vaccine using cells obtained from each patient’s tumor. A gene, called GM-CSF, is placed into the cancer cells to change the surface of the cells so the body can identify the cells as cancerous. Once the vaccine is injected, the body’s immune cells come to the injection site and start to work with lymphocytes, immune cells that help rid the body of an infection.
“We’re trying to turn on the lymphocytes so they can identify the cancer cells and clear it, just like the body clears the cold or flu virus or an infection,” Dr. Nemunaitis said.
Three patients with advanced stage lung cancer experienced complete remission of their disease lasting six months, 18 months and ongoing at 22 months. For two of these patients, prior treatment with chemotherapy had failed. One patient experienced a 30-percent decrease in the size of a lung nodule, and for seven patients, their disease remained stable and did not progress for a period ranging from almost five months to more than 28 months.
“These results are very promising for patients with non-small cell lung cancer, which is frequently resistant to chemotherapy,” Dr. Nemunaitis said. “We believe this study is the first time immune therapy has been the sole treatment associated with complete and durable regression of metastatic NSCLC lesions, particularly those lasting more than one year, as observed in two patients in our study.”
While chemotherapy is an option for patients with advanced disease, results show a 15 to 21 percent response rate, median survival of 7.4 to 8.2 months and one year overall survival of 31 to 36 percent. Early-stage patients undergoing complete surgical resection have a greater than 75 percent chance of surviving one year, but survival is reduced to 35 to 50 percent at five years largely as a result of disease that recurs.
Dr. Nemunaitis conducted his research through the Baylor Research Institute and the Mary Crowley Medical Research Center at Baylor. The center is one of the largest patient treatment sites for gene therapy in the country and is supported by gifts from Home Interiors & Gifts, Don and Linda Carter, Ruth Shanahan, Mr. H.T. Ardinger, Jr., and the E.K. Boon Family. For more information about cancer research studies at the Mary Crowley Medical Research Center at Baylor University Medical Center at Dallas, visit www.MCMRC.com.
Baylor University Medical Center at Dallas is a leading patient care and research center for the Southwest. With more than 1,000 beds and 900 physicians on staff, Baylor is recognized by U.S. News & World Report among America’s best hospitals in a range of medical specialties. Currently at Baylor, more than 500 research protocols are under way.
Cite This Page: